Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10543337
Nitric oxide delivery devices
granted -
US 10543280
Stabilization of biomolecules using sugar polymers
granted -
US 10537528
Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
granted -
US 10537596
Bone marrow adipose portion isolation device and methods
granted -
US 10537535
Histone deacetylase inhibitors
granted -
US 10537553
Methods of treating muscular dystrophy
granted -
US 10537635
Detection of arginine methylation of EGFR for prediction of resistance to therapy
granted -
US 10538762
Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
granted -
US 10537529
Cell-free methods of producing vault particles and vault particles resulting therefrom
granted -
US 10538579
Bispecific pertussis antibodies
granted -
US 10533056
Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
granted -
US 10532040
Methods of treating cancer with herbacetin
granted -
US 10531680
Creatine ester pronutrient compounds and formulations
granted -
US 10533190
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10533227
Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
granted -
US 10533997
Reverse genetics system of Zika virus
granted -
US 10533159
Pichinde virus reverse genetics systems and methods of use
granted -
US 10533186
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
granted -
US 10532109
Peptide-DNA chimeras for treatment of HER overexpressing cancers
granted -
US 10526576
Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells
granted -
US 10526400
Humanized pertussis antibodies and used thereof
granted -
US 10526359
Thiosaccharide mucolytic agents
granted -
US 10526619
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10526373
Peptide showing melanin generation-promoting activity and use thereof
granted -
US 10526656
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
granted -
US 10517948
Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
granted -
US 10517898
Compositions and methods related to hematologic recovery
granted -
US 10519467
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10517917
Compositions and methods for preventing or treating pulmonary hypertension
granted -
US 10520499
Methods of diagnosing and treating autism
granted -
US 10520517
Disease severity index for assessment of chronic liver disease
granted -
US 10519247
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
granted -
US 10519205
Compositions and methods for use of anion channel rhodopsins
granted -
US 10519423
High efficiency reprogramming of fibroblasts into cardiomyocytes
granted -
US 10517491
Cardiac phase-resolved non-breath-hold 3-dimensional magnetic resonance angiography
granted -
US 10517942
Polypeptide glycopeptide fragments from the V1/V2 and V3 domains of the HIV-1 envelope protein gp 120
granted -
US 10518074
Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same
granted -
US 10518002
Intraocular drug delivery and filter device and methods of using same
granted -
US 10519188
Cyclic di-nucleotide compounds and methods of use
granted -
US 10512630
Compositions and methods for treating cancer
granted -
US 10512667
Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
granted -
US 10512691
Systems and methods for targeted imaging and ablation of cardiac cells
granted -
US 10512672
Methods for the treatment of inflammatory joint disease
granted -
US 10512687
Compositions and methods for enhanced innate immunity
granted -
US 10512669
Blockade of inflammatory proteases with cyclic peptides
granted -
US 10513587
Self-integrating hydrogels and methods for making the same
granted -
US 10513712
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10507239
V1/V2 fragments of a HIV-1 envelope glycoprotein
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory